The Enhancing Oncology Model allows pooling of groups of practices for quality measurement, which was not permitted under the OCM.
Moderator Stuart Staggs, MSIE, senior director, strategic programs, The US Oncology Network, and our panelists discuss a provision of the Enhancing Oncology Model (EOM) which would allow pooling of smaller practices into a larger group for quality measurement purposes. Not everyone thinks it's great idea. Panelists Stephen Schleicher, MD, MBA, chief medical officer, Tennessee Oncology, Kashyap Patel, MD, CEO, Carolina Blood and Cancer Care Associates and Community Oncology Alliance president, and Fred Divers, MD, chief medical officer, American Oncology Network and medical oncologist, Genesis Cancer and Blood Institute of Arkansas, discuss the concept.
For Community Oncology, Good News in PFS Offset by Potential Wreckage of MFP Proposal
July 15th 2025CMS proposes the 2026 Physician Fee Schedule (PFS), addressing payment disparities in oncology, but the community oncology community warns of financial threats from the Inflation Reduction Act. Updates reflect late Tuesday release of the proposed 2026 schedule for the Hospital Outpatient Prospective Payment System.
Read More
Using AI for the Medical Note: Game Changer or a Bridge Too Far?
July 9th 2025During the “Tech Innovations in Community Oncology” meeting from Tennessee Oncology, oncologists explore artificial intelligence (AI) tools like DeepScribe to enhance documentation efficiency, reduce burnout, and improve patient engagement in clinical settings.
Read More
How AI Can Address the Troubled Business Model in Oncology
July 7th 2025Artificial intelligence (AI) will transform community oncology, addressing workforce shortages and reimbursement challenges while enhancing patient care and operational efficiency, discussed speakers at Tennessee Oncology's “Tech Innovations in Community Oncology."
Read More
Alexander I. Spira, MD, PhD, of The US Oncology Network, discusses findings from the COCOON trial that show prophylactic treatment reduces dermatological adverse events in patients with non–small cell lung cancer (NSCLC), enhancing their quality of life during amivantamab therapy.
Read More